Kyprolis (carfilzomib, PR-171)
by Jessica Langholtz
Updated: Dec 9, 2009
Updated: Dec 9, 2009
| Brand Name: | Kyprolis |
| Generic Name: | carfilzomib |
| Useful Links: | News articles, forum discussions |
| Code Name: | PR-171 |
| Company: | Onyx Pharmaceuticals |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Kyprolis, which is a second-generation proteasome inhibitor, selectively targets the enzymes that break down important proteins in cancerous cells. Multiple early-stage studies have shown that carfilzomib has an encouraging safety profile, with low levels of neuropathy (a common side effect for many myeloma treatments). A Phase 2 trial with relapsed and refractory myeloma patients has recently closed enrollment, and results are expected in late 2010.
Clinical Trials:
For a list of clinical trials studying carfilzomib for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official Web site for Carfilzomib: http://www.kyprolis.com
Related Articles:
- Once-Weekly High-Dose Kyprolis Yields Deeper Responses And Longer Remissions Than Twice-Weekly Kyprolis (ASCO & EHA 2018)
- FDA Approves Once-Weekly Dosing And Revised Safety Information For Kyprolis
- Common Measures Of Heart And Blood Vessel Health May Predict Risk Of Heart-Related Side Effects During Treatment With Kyprolis
- Eyelid-Related Complications Of Velcade Therapy: New Insights And Recommendations
- ASCO 2018 Update – Expert Perspectives On The Key Multiple Myeloma-Related Oral Presentations
